ArticleBMC nephrology2026
Comparative efficacy and safety of anticoagulation strategies in continuous renal replacement therapy: a real-world cohort study.
Article in BMC nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundThe optimal anticoagulation strategy for continuous renal replacement therapy (CRRT) remains controversial. Real-world comparisons of contemporary agents-regional citrate anticoagulation (RCA), nafamostat mesylate (NM), and unfractionated heparin (UH)-are limited.
methodsIn this single-center retrospective cohort study, we analyzed 420 CRRT sessions (from 197 unique patients) conducted in four intensive care unit (ICU) wards at an academic medical center in China between September 2025 and November 2025. The primary efficacy outcome was filter lifespan, with Restricted Mean Survival Time (RMST) analysis adopted as the primary method (due to violation of the proportional hazards assumption). Propensity score matching (PSM) and mixed-effects Cox models were used as sensitivity analyses, adjusting for patient, treatment, ward, and machine factors. Multiplicity adjustment (Holm-Bonferroni) was applied for pairwise comparisons.
resultsAmong 420 sessions, RCA was the most frequently used approach (59.0%), followed by NM (21.2%), UH (12.6%), and no anticoagulation (4.0%). Median filter lifespan was longest with RCA (65.5 h, IQR 48.0-72.0) compared to NM (32.0 h, IQR 15.5-52.5), UH (40.0 h, IQR 26.0-72.0), and no anticoagulation (12.5 h, IQR 6.0-19.5; P < 0.001). RMST analysis confirmed that RCA was associated with significantly longer mean filter survival time compared to NM (difference 18.2 h, 95% CI 10.5-25.9; adjusted P < 0.001) and UH (difference 14.6 h, 95% CI 5.8-23.4; adjusted P = 0.046). The NM vs. UH comparison showed no significant difference (difference - 3.6 h, 95% CI -12.1 to 4.9; adjusted P = 0.52). After PSM, results remained consistent. Major bleeding events were rare (n = 9, 2.1%), but the small number of events precludes meaningful between-group safety comparison. However, 20.9% of RCA sessions failed to achieve the protocol-specified post-filter ionized calcium target, reflecting a metabolic calcium monitoring challenge unique to citrate anticoagulation. Twenty-eight-day mortality (patient-level analysis, n = 197) did not differ significantly across groups after adjustment (overall 36.5%, 72/197).
conclusionIn this retrospective data analysis of real-world practice, RCA provided superior filter lifespan compared to NM and UH for CRRT, while NM showed intermediate efficacy. Although major bleeding events were uncommon, the small number of events precludes definitive safety conclusions. Vigilant monitoring remains necessary regardless of the agent employed. The choice of anticoagulation should balance filter efficacy, bleeding risk, metabolic monitoring capabilities, and institutional resources.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.